Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer.

@article{Kao2012OpenMP,
  title={Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer.},
  author={Chien-Chang Kao and Y Chang and Tony Wu and Guang-Huan Sun and Dah-Shyong Yu and S Chang and T L Cha},
  journal={Journal of the Chinese Medical Association : JCMA},
  year={2012},
  volume={75 6},
  pages={255-61}
}
BACKGROUND To evaluate the efficacy and safety of administering a 3-month formulation of triptorelin as part of disease management of Taiwanese men with advanced adenocarcinoma of the prostate. METHODS Patients with newly diagnosed, locally advanced, or metastatic adenocarcinoma of the prostate were enrolled in our study, after informed consent was obtained. All patients received bicalutamide 50 mg daily for 28 days, starting 7 days before the first injection of triptorelin. A dosage of 11.25… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Prostate cancer in Taiwan: epidemiology and risk factors.

International journal of andrology • 2000
View 1 Excerpt

Long-term results with a long-acting formulation of D-TRP-6 LHRH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study. Prostate 1987;11:243e5

F Boccardo, D Decensi Guarneri, A Rubagotti, T Massa, G Martorana
1987
View 1 Excerpt

Similar Papers

Loading similar papers…